NCT01696383View on ClinicalTrials.gov

Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)

One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01696383 - Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia | Biotech Hunter | Biotech Hunter